

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently amended) A therapeutic composition comprising a first agent that targets an interleukin-15 receptor (IL-15R) and a second agent that targets an interleukin-2 receptor (IL-2R), wherein the first agent comprises a mutant IL-15 polypeptide that binds an IL-15R but fails to fully activate signal transduction through the IL-15R, the mutant IL-15 polypeptide being optionally fused to the Fc region of an immunoglobulin, and the second agent comprises an IL-2 polypeptide that binds an IL-2R, the IL-2 polypeptide being optionally fused to the Fc region of an immunoglobulin.

2-34. (Canceled)

35. (New) The therapeutic composition of claim 1, wherein the mutant IL-15 polypeptide binds an IL-15R α subunit of an IL-15R.

36. (New) The therapeutic composition of claim 1, wherein the immunoglobulin is an immunoglobulin of the G class (an IgG).

37. (New) The therapeutic composition of claim 36, wherein the mutant IL-15 polypeptide has a mutation at position 156 of SEQ ID NO:2.

38. (New) The therapeutic composition of claim 37, wherein the mutant IL-15 polypeptide also has a mutation at position 149 of SEQ ID NO:2.

39. (New) The therapeutic composition of claim 37, wherein the mutation at position 156 of SEQ ID NO:2 is a substitution of aspartate for glutamine.

40. (New) The therapeutic composition of claim 38, wherein the mutation at position 149 of SEQ ID NO:2 is a substitution of aspartate for glutamine.

41. (New) The therapeutic composition of claim 38, wherein the mutant IL-15 polypeptide has a substitution of aspartate for glutamine at positions 149 and 156 of SEQ ID NO:2.

42. (New) The therapeutic composition of claim 1, further comprising rapamycin.

43. (New) The therapeutic composition of claim 1, wherein the mutant IL-15 polypeptide is at least 90% identical to wild-type IL-15.

44. (New) The therapeutic composition of claim 1, wherein the Fc region of an immunoglobulin, when present and fused to the mutant IL-15 polypeptide or the IL-2 polypeptide, is a target-cell depleting Fc region.

45. (New) A therapeutic composition comprising a first agent that targets an interleukin-15 receptor (IL-15R) and a second agent that targets an interleukin-2 receptor (IL-2R), wherein the first agent consists of a mutant IL-15 polypeptide that binds an IL-15R but fails to fully activate signal transduction through the IL-15R, the mutant IL-15 polypeptide being optionally fused to the Fc region of an immunoglobulin, and the second agent consists of an IL-2 polypeptide that binds an IL-2R, the IL-2 polypeptide being optionally fused to the Fc region of an immunoglobulin.

46. (New) The therapeutic composition of claim 45, wherein the mutant IL-15 polypeptide is not fused to the Fc region of an immunoglobulin and the IL-2 polypeptide is fused to the Fc region of an immunoglobulin.